Committed to the Development of Proprietary Antiviral Peptides and Monoclonal Antibodies for Treating Debilitating Infectious Diseases.

 

Committed to the Development of Proprietary Antiviral Peptides and Monoclonal Antibodies for Treating Debilitating Infectious Diseases.

40

Years of Drug
Development

Innovative Solutions

Welcome to
Enzolytics Inc.

https://enzolytics.com/wp-content/uploads/2021/01/line_03.png

Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind.

Discover More

How We Help

Our Mission

https://enzolytics.com/wp-content/uploads/2021/01/line_03.png

Our mission is clear – to create therapeutics that are effective and affordable, for treating infectious diseases that plague the world. This goal includes development of therapeutics and monoclonal antibodies targeting infectious diseases, including the CoronaVirus. Our ultimate objective is to provide such therapeutics to improve health around the world

Enzolytics, Inc. is Texas based biotech company committed to the development and commercialization of its proprietary proteins and monoclonal antibodies for the treatment of infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s multiple therapeutics also are being developed to treat Rheumatoid Arthritis and certain forms of cancer. Our technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19.

Discover More

Enzolytics is a Texas based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested its anti-HIV therapeutics known as ITV-1. ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union where it demonstrated beneficial outcomes. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.

The Company’s scientific team, Harry Zhabilov, Joseph Cotropia MD and Gaurav Chandra MD, pioneered the Company’s proprietary therapeutics for treating infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s therapeutics may also be used to treat Rheumatoid Arthritis and certain forms of cancer.

Discover More

Enzolytics, Inc. is committed to the development and commercialization of its proprietary therapeutics for the treatment of debilitating infectious diseases. The Company’s technology is broad, including technology for treating HIV-1, Hepatitis (A, B, C), Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus and diphtheria. The Company’s therapies are also being developed to treat chronic infection and certain forms of cancer.

As a result of the recent acquisition of the biotech company BioClonetics Immunotherapeutics, Inc., Enzolytics is now advancing additional complementary therapeutic platforms for treating infectious diseases, including a focus on production of anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies to treat COVID-19.

Discover More

The Company protects its technology through an aggressive strategy to cover its intellectual property. The Company’s intellectual property includes:

Issued Patents

Enzolytics is the owner of the following issued U.S. Patents covering its technology relating to a peptide that has been demonstrated in clinical trials to provide anti-HIV-1 retroviral benefit in vivo.

  • U.S. Patent No. 7,479,538, issued January 20, 2009, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing and Treating HIV
  • U.S. Patent No. 8,066,982, issued November 29, 2011, entitled Irreversibly-Inactivated Pepsinogen Fragment and Pharmaceutical Compositions Comprising the Same for Detecting, Preventing and Treating HIV.
Discover More

Tested Antiviral Therapeutics

Enzolytics is a Texas based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus.

Our Lab Locations

The Dallas Texas Metroplex

Texas A&M University Institute for Preclinical Studies College Station Texas

Our Partnering Labs for
Implementing Our Technologies

Genscript Labs https://www.genscript.com/overview.html?src=pullmenu

Production of Recombinant Monoclonal Antibodies (necessary for human treatment) against numerous infectious diseases.

University of Strasbourg, France https://www.virology-education.com/christiane-moog-phd-hdr/

Dr. Christiane Moog, MD, Research Director at INSERM U1109, HDR PBMC in vitro neutralization testing of our anti-HIV monoclonal antibodies.

California National Primate Research Center https://www.ucdavis.edu/research/partnerships

Koen Van Rompay, D.V.M., PhD, Univ. of California Davis, California, Koen Van Rompay,

Macaque trials of anti-HIV Monoclonal Antibodies.

Denver Scientific

Artificial Intelligence used to identify conserved virus sites against which neutralizing Monoclonal Antibodies targeting numerous viruses are being produced.